127 related articles for article (PubMed ID: 19458626)
21. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
22. Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy.
Song JH; Cho KM; Kim HJ; Kim YK; Kim NY; Kim HJ; Lee TH; Hwang SY; Kim TS
Oncol Rep; 2015 Jul; 34(1):488-94. PubMed ID: 25955569
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
24. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
25. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
Ohta T; Hori H; Ogawa M; Miyahara M; Kawasaki H; Taniguchi N; Komada Y
Oncol Rep; 2004 Nov; 12(5):1115-20. PubMed ID: 15492802
[TBL] [Abstract][Full Text] [Related]
26. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
27. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
[TBL] [Abstract][Full Text] [Related]
28. [Observation and care in high-dose cytarabine treatment of acute myelogenous leukemia].
Xi YR; Tu YL; Zhao XH
Zhonghua Hu Li Za Zhi; 1996 Nov; 31(11):653-5. PubMed ID: 9304928
[No Abstract] [Full Text] [Related]
29. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
30. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
[TBL] [Abstract][Full Text] [Related]
31. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
Bhatla D; Gerbing RB; Alonzo TA; Conner H; Ross JA; Meshinchi S; Zhai X; Zamzow T; Mehta PA; Geiger H; Perentesis J; Davies SM
Br J Haematol; 2009 Feb; 144(3):388-94. PubMed ID: 19036079
[TBL] [Abstract][Full Text] [Related]
32. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics of cytarabine in childhood leukemia.
Lamba JK
Pharmacogenomics; 2011 Dec; 12(12):1629-32. PubMed ID: 22118048
[No Abstract] [Full Text] [Related]
34. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
35. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
36. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Lech-Maranda E; Seweryn M; Giebel S; Holowiecki J; Piatkowska-Jakubas B; Wegrzyn J; Skotnicki A; Kielbinski M; Kuliczkowski K; Paluszewska M; Jedrzejczak WW; Dutka M; Hellmann A; Flont M; Zdziarska B; Palynyczko G; Konopka L; Szpila T; Gawronski K; Sulek K; Sokolowski J; Kloczko J; Warzocha K; Robak T
Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
[TBL] [Abstract][Full Text] [Related]
37. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
Flasshove M; Strumberg D; Ayscue L; Mitchell BS; Tirier C; Heit W; Seeber S; Schütte J
Leukemia; 1994 May; 8(5):780-5. PubMed ID: 7514246
[TBL] [Abstract][Full Text] [Related]
38. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group.
Phillips CL; Lane A; Gerbing RB; Alonzo TA; Wilkey A; Radloff G; Lange B; Gamazon ER; Dolan ME; Davies SM
Clin Cancer Res; 2020 Jun; 26(12):2891-2897. PubMed ID: 32122921
[TBL] [Abstract][Full Text] [Related]
39. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
40. Induction therapy for elderly patients with acute myeloid leukemia.
Martin MG; Abboud CN
Blood Rev; 2008 Nov; 22(6):311-20. PubMed ID: 18539373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
